The Wagner Firm Announces Investigation of AngioDynamics, Inc.

The Wagner Firm announces that it is investigating potential claims on behalf of investors of AngioDynamics, Inc. (“AngioDynamics” or the “Company”) (NASDAQ: ANGO) concerning the Company’s and its officers’ possible violations of federal securities laws by misleading investors regarding AngioDynamics’ business, operations and prospects, including the future prospects of the Company’s Morpheus line of products.

AngioDynamics is a provider of minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. The investigation relates to the Company’s announcements of its financial results for the first quarter 2016. On October 8, 2015, the Company announced a loss of $0.02 per share, on net sales of $83.7 million. The Company attributed its poor financial performance to the withdrawal of its Morpheus PICC line from the market. On this news shares of AngioDynamics fell $0.88, or 7%, to close on October 9, 2015 at $12.23 per share, thereby damaging investors. The Wagner Firm is preparing a lawsuit to recover investment losses suffered by AngioDynamics investors.

If you purchased AngioDynamics shares prior to October 9, 2015, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Avi Wagner, Esquire, of The Wagner Firm, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, at (310) 491-7949, by e-mail at info@thewagnerfirm.com, or visit our website at http://thewagnerfirm.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151028006252/en/